Corruption in China: Part 2 – The Bribery Schemes

Published date19 June 2019
Subject MatterFCPA,Compliance,Bribery,Kickbacks,Medical Devices,China,Third-Party,Corruption,White Collar Crimes,Enforcement Actions,GlaxoSmithKline,Pharmaceutical Industry
Law FirmThomas Fox

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT